Literature DB >> 12603605

An abnormal but functionally active complement component C9 protein found in an Irish family with subtotal C9 deficiency.

Ann Orren1, Ann M O'Hara, B Paul Morgan, Anthony P Moran, Reinhard Würzner.   

Abstract

Two independently segregating C9 genetic defects have previously been reported in two siblings in an Irish family with subtotal C9 deficiency. One defect would lead to an abnormal C9 protein, with replacement of a cysteine by a glycine (C98G). The second defect is a premature stop codon at amino acid 406 which would lead to a truncated C9. However, at least one of two abnormal proteins was present in the circulation of the proband at 0.2% of normal C9 concentration. In this study, the abnormal protein was shown to have a molecular weight approximately equal to that of normal C9, and to carry the binding site for monoclonal antibody (mAb) Mc42 which is known to react with an epitope at amino acid positions 412-426, distal to 406. Therefore, the subtotal C9 protein carries the C98G defect. The protein was incorporated into the terminal complement complex, and was active in haemolytic, bactericidal and lipopolysaccharide release assays. A quantitative haemolytic assay indicated even slightly greater haemolytic efficiency than normal C9. Epitope mapping with six antihuman C9 mAbs showed the abnormal protein to react to these antibodies in the same way as normal C9. However, none of these mAbs have epitopes within the lipoprotein receptor A module, where the C98G defect is located. The role of this region in C9 functionality is still unclear. In conclusion, we have shown that the lack of a cysteine led to the production of a protein present in the circulation at very much reduced levels, but which was fully functionally active.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12603605      PMCID: PMC1782909          DOI: 10.1046/j.1365-2567.2003.01587.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  35 in total

1.  THE BIOSYNTHESIS OF CELL WALL LIPOPOLYSACCHARIDE IN ESCHERICHIA COLI. I. THE BIOCHEMICAL PROPERTIES OF A URIDINE DIPHOSPHATE GALACTOSE 4-EPIMERASELESS MUTANT.

Authors:  A D ELBEIN; E C HEATH
Journal:  J Biol Chem       Date:  1965-05       Impact factor: 5.157

2.  Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies.

Authors:  R Würzner; M Schulze; L Happe; A Franzke; F A Bieber; M Oppermann; O Götze
Journal:  Complement Inflamm       Date:  1991

3.  Immune lytic transformation: a state of irreversible damage generated as a result of the reaction of the eighth component in the guinea pig complement system.

Authors:  R L Stolfi
Journal:  J Immunol       Date:  1968-01       Impact factor: 5.422

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Complement-mediated lipopolysaccharide release and outer membrane damage in Escherichia coli J5: requirement for C9.

Authors:  A M O'Hara; A P Moran; R Würzner; A Orren
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

Review 6.  Inherited deficiencies of the terminal components of human complement.

Authors:  R Würzner; A Orren; P J Lachmann
Journal:  Immunodefic Rev       Date:  1992

7.  Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals.

Authors:  R Würzner; A Orren; P Potter; B P Morgan; D Ponard; P Späth; M Brai; M Schulze; L Happe; O Götze
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

8.  Antigenic and immunogenic differences in lipopolysaccharides of Escherichia coli J5 vaccine strains of different origins.

Authors:  B J Appelmelk; J J Maaskant; A M Verweij-van Vught; N M van der Meer; B G Thijs; D M MacLaren
Journal:  J Gen Microbiol       Date:  1993-11

9.  Mutations in the putative lipid-interaction domain of complement C9 result in defective secretion of the functional protein.

Authors:  M Dupuis; M C Peitsch; U Hamann; K K Stanley; J Tschopp
Journal:  Mol Immunol       Date:  1993-01       Impact factor: 4.407

10.  Hereditary deficiency of the seventh component of complement and recurrent meningococcal infection: investigations of an Irish family using a novel haemolytic screening assay for complement activity and C7 M/N allotyping.

Authors:  L J Egan; A Orren; J Doherty; R Würzner; C F McCarthy
Journal:  Epidemiol Infect       Date:  1994-10       Impact factor: 2.451

View more
  2 in total

Review 1.  Deficiencies of the complement MAC II gene cluster (C6, C7, C9): is subtotal C6 deficiency of particular evolutionary benefit?

Authors:  R Würzner
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

2.  Interference of the Zika Virus E-Protein With the Membrane Attack Complex of the Complement System.

Authors:  Zahra Malekshahi; Britta Schiela; Sarah Bernklau; Zoltan Banki; Reinhard Würzner; Heribert Stoiber
Journal:  Front Immunol       Date:  2020-10-28       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.